Cellular Biomedicine Group, Inc. Form 8-K November 14, 2013

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2013

CELLULAR BIOMEDICINE GROUP, INC.

(Exact name of registrant as specified in its charter)

Delaware	0-52282	86-1032927
(State or other	(Commission File	(IRS Employer
Jurisdiction of	Number)	Identification No.)
Incorporation)		

. ,

530 University Avenue, #17

Palo Alto, California 94301 (Address of Principal (Zip Executive Offices) Code)

Registrant's telephone number, including area code: (650) 566-5064

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

Item 7.01 Regulation FD Disclosure

Attached as Exhibit 99.1 to this Current Report is the form of presentation that the Cellular Biomedicine Group, Inc. (the "Company") expects to use in connection with presentations to certain potential investors in the Company.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

99.1 Presentation

Edgar Filing: Cellular Biomedicine Group, Inc. - Form 8-K

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cellular Biomedicine Group, Inc.

Date: November 14, 2013 By: /s/ Andrew Chan

Andrew Chan

Chief Financial Officer